MedTrace Logo

Estrogen Use in Protection From Cognitive Decline

NCT00097058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 71

Last updated 2014-11-19

No results posted yet for this study

Summary

This study is designed to assess the effects of estrogen therapy among postmenopausal women at risk for cognitive decline.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Natalie Rasgon, MD, PhD · Stanford University School of Medicine, Dept of Psychiatry and Behavioral Sciences

  • Terence Ketter, MD · Stanford University

  • Jerome Yesavage, MD · Stanford University

  • Jennifer Hoblyn, MD · VA Palo Alto Health Care System

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00097058 on ClinicalTrials.gov